D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company’s stock. D. Boral Capital’s price objective indicates a potential upside of 204.83% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright raised their price objective on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. WBB Securities reiterated a “strong-buy” rating and set a $45.00 target price on shares of Omeros in a research report on Wednesday, October 15th. Wall Street Zen cut Omeros from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.33.

Omeros Price Performance

Shares of NASDAQ OMER opened at $11.81 on Tuesday. The company has a 50-day simple moving average of $11.88 and a 200-day simple moving average of $7.48. The company has a market cap of $837.33 million, a PE ratio of -5.85 and a beta of 2.38. Omeros has a 12 month low of $2.95 and a 12 month high of $17.65.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.39. On average, analysts anticipate that Omeros will post -3.09 EPS for the current year.

Insider Activity at Omeros

In other news, CAO David J. Borges sold 30,000 shares of Omeros stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 12.90% of the stock is currently owned by company insiders.

Institutional Trading of Omeros

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC lifted its position in Omeros by 16.5% during the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 1,004 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Omeros by 113.1% in the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 5,677 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in shares of Omeros in the 2nd quarter valued at $32,000. Tower Research Capital LLC TRC lifted its holdings in shares of Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 11,971 shares in the last quarter. Finally, Sei Investments Co. purchased a new stake in Omeros during the 2nd quarter worth $40,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.